Heme oxygenase-1 silencing increases the sensitivity of human osteosarcoma MG63 cells to arsenic trioxide

Molecular and Cellular Biochemistry

Volumn 392, Issue 1-2, 2014, Pages 135-144

  Zhong, Lingzhi ^a   Wang, Yang ^a,b   Li, Wenxue ^a   Gu, Junlian ^a   Li, Xiuying ^a   Wang, Xiaotong ^a   Yue, Zhen ^a   Mu, Yan ^a   Bai, Jinping ^a   Li, Ronggui ^a   Zhang, Haiying ^a  

^a Basic Medical College   (China)

^b SHENZHEN PEOPLE'S HOSPITAL   (China)

Author keywords

Arsenic; HO 1; MG63; Osteosarcoma; shRNA

Indexed keywords

ANTIINFECTIVE AGENT; ARSENIC TRIOXIDE; HEME OXYGENASE 1; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA; ORGANOARSENIC DERIVATIVE; OXIDE; PRIMER DNA;

APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME INDUCTION; HUMAN; HUMAN CELL; IC 50; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; BONE TUMOR; DRUG EFFECTS; GENE SILENCING; GENETICS; METABOLISM; OSTEOSARCOMA; PATHOLOGY; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

APOPTOSIS; ARSENICALS; BASE SEQUENCE; BONE NEOPLASMS; CELL LINE, TUMOR; DNA PRIMERS; GENE SILENCING; HEME OXYGENASE-1; HUMANS; OSTEOSARCOMA; OXIDES; POLYMERASE CHAIN REACTION; REACTIVE OXYGEN SPECIES;

EID: 84905174772     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-014-2027-1     Document Type: Article

References (28)

1. Siclari VA, Qin L (2010) Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 5(1):78-87
2. Marina N, Gebhardt M, Teot L, Gorlick R (2004) Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9(4):422-441 (Pubitemid 39014554)
3. Ferrari S, Palmerini E (2007) Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 19(4):341-346 (Pubitemid 46883523)
4. Pakos EE, Nearchou AD, Grimer RJ, Koumoullis HD, Abudu A, Bramer JA, Jeys LM, Franchi A, Scoccianti G, Campanacci D, Capanna R, Aparicio J, Tabone MD, Holzer G, Abdolvahab F, Funovics P, Dominkus M, Ilhan I, Berrak SG, Patino-Garcia A, Sierrasesumaga L, San-Julian M, Garraus M, Petrilli AS, Filho RJ, Macedo CR, Alves MT, Seiwerth S, Nagarajan R, Cripe TP, Ioannidis JP (2009) Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer 45(13):2367-2375
5. Emadi A, Gore SD (2010) Arsenic trioxide - an old drug rediscovered. Blood Rev 24(4-5):191-199
6. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, Ferrara F, Fazi P, Cicconi L, Di Bona E, Specchia G, Sica S, Divona M, Levis A, Fiedler W, Cerqui E, Breccia M, Fioritoni G, Salih HR, Cazzola M, Melillo L, Carella AM, Brandts CH, Morra E, von Lilienfeld-Toal M, Hertenstein B, Wattad M, Lubbert M, Hanel M, Schmitz N, Link H, Kropp MG, Rambaldi A, La Nasa G, Luppi M, Ciceri F, Finizio O, Venditti A, Fabbiano F, Dohner K, Sauer M, Ganser A, Amadori S, Mandelli F, Dohner H, Ehninger G, Schlenk RF, Platzbecker U (2013) Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med 369(2):111-121
7. Mayor S (2013) Arsenic trioxide combination improves survival in APL. Lancet Oncol 14(9):e346
8. Mi JQ, Li JM, Shen ZX, Chen SJ, Chen Z (2012) How to manage acute promyelocytic leukemia. Leukemia 26(8):1743-1751
9. 3) on human breast cancer cells. J Cell Biochem 93(1):173-187
10. Mann KK, Wallner B, Lossos IS, Miller WH Jr (2009) Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opin Investig Drugs 18(11):1727-1734
11. Li Y, Qu X, Qu J, Zhang Y, Liu J, Teng Y, Hu X, Hou K, Liu Y (2009) Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Cancer Lett 284(2):208-215
12. Yoda A, Toyoshima K, Watanabe Y, Onishi N, Hazaka Y, Tsukuda Y, Tsukada J, Kondo T, Tanaka Y, Minami Y (2008) Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. J Biol Chem 283(27):18969-18979
13. Fei M, Lu M, Wang Y, Zhao Y, He S, Gao S, Ke Q, Liu Y, Li P, Cui X, Shen A, Cheng C (2009) Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization. Med Oncol 26(2):178-185
14. Barrera LN, Rushworth SA, Bowles KM, MacEwan DJ (2012) Bortezomib induces heme oxygenase-1 expression in multiple myeloma. Cell Cycle 11(12):2248-2252
15. Wang Y, Wei Y, Zhang H, Shi Y, Li Y, Li R (2012) Arsenic trioxide induces apoptosis of p53 null osteosarcoma MG63 cells through the inhibition of catalase. Med Oncol 29(2):1328-1334
16. Smith DM, Patel S, Raffoul F, Haller E, Mills GB, Nanjundan M (2010) Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells. Cell Death Differ 17(12):1867-1881
17. Yedjou CG, Moore P, Tchounwou PB (2006) Dose- and time-dependent response of human leukemia (HL-60) cells to arsenic trioxide treatment. Int J Environ Res Public Health 3(2):136-140 (Pubitemid 350002697)
18. Huan SY, Yang CH, Chen YC (2000) Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy. Leuk Lymphoma 38(3-4):283-293 (Pubitemid 30303662)
19. Engel RH, Evens AM (2006) Oxidative stress and apoptosis: a new treatment paradigm in cancer. Front Biosci 11:300-312 (Pubitemid 43253493)
20. Liu SX, Athar M, Lippai I, Waldren C, Hei TK (2001) Induction of oxyradicals by arsenic: implication for mechanism of genotoxicity. Proc Natl Acad Sci USA 98(4):1643-1648 (Pubitemid 32165551)
21. Primon M, Huszthy PC, Motaln H, Talasila KM, Torkar A, Bjerkvig R, Lah Turnsek T (2013) Cathepsin L silencing enhances arsenic trioxide mediated in vitro cytotoxicity and apoptosis in glioblastoma U87MG spheroids. Exp Cell Res 319((17)):2637-2648
22. Overholtzer M, Rao PH, Favis R, Lu XY, Elowitz MB, Barany F, Ladanyi M, Gorlick R, Levine AJ (2003) The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability. Proc Natl Acad Sci USA 100(20):11547-11552 (Pubitemid 37205973)
23. Ueda Y, Dockhorn-Dworniczak B, Blasius S, Mellin W, Wuisman P, Bocker W, Roessner A (1993) Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol 119(3):172-178
24. Goto A, Kanda H, Ishikawa Y, Matsumoto S, Kawaguchi N, Machinami R, Kato Y, Kitagawa T (1998) Association of loss of heterozygosity at the p53 locus with chemoresistance in osteosarcomas. Jpn J Cancer Res 89(5):539-547 (Pubitemid 28302120)
25. Wu X, Shi J, Wu Y, Tao Y, Hou J, Meng X, Hu X, Han Y, Jiang W, Tang S, Zangari M, Tricot G, Zhan F (2011) Arsenic trioxide-mediated growth inhibition of myeloma cells is associated with an extrinsic or intrinsic signaling pathway through activation of TRAIL or TRAIL receptor 2. Cancer Biol Ther 10(11):1201-1214
26. Sanchez Y, Calle C, de Blas E, Aller P (2009) Modulation of arsenic trioxide-induced apoptosis by genistein and functionally related agents in U937 human leukaemia cells. Regulation by ROS and mitogen-activated protein kinases. Chem Biol Interact 182(1):37-44
27. Wang Y, Xu Y, Wang H, Xue P, Li X, Li B, Zheng Q, Sun G (2009) Arsenic induces mitochondria-dependent apoptosis by reactive oxygen species generation rather than glutathione depletion in Chang human hepatocytes. Arch Toxicol 83(10):899-908
28. Das J, Ghosh J, Manna P, Sinha M, Sil PC (2009) Taurine protects rat testes against NaAsO(2)-induced oxidative stress and apoptosis via mitochondrial dependent and independent pathways. Toxicol Lett 187(3):201-210